GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Square Pharmaceuticals PLC (DHA:SQURPHARMA) » Definitions » ROC %

Square Pharmaceuticals (DHA:SQURPHARMA) ROC % : 20.26% (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Square Pharmaceuticals ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Square Pharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Dec. 2024 was 20.26%.

As of today (2025-04-16), Square Pharmaceuticals's WACC % is 10.54%. Square Pharmaceuticals's ROC % is 18.83% (calculated using TTM income statement data). Square Pharmaceuticals generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Square Pharmaceuticals ROC % Historical Data

The historical data trend for Square Pharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Square Pharmaceuticals ROC % Chart

Square Pharmaceuticals Annual Data
Trend Mar15 Mar16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.07 24.48 23.56 19.94 19.82

Square Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.80 19.82 13.42 21.06 20.26

Square Pharmaceuticals ROC % Calculation

Square Pharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Jun. 2024 is calculated as:

ROC % (A: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jun. 2023 ) + Invested Capital (A: Jun. 2024 ))/ count )
=18202.565 * ( 1 - 19.32% )/( (70097.623 + 78120.431)/ 2 )
=14685.829442/74109.027
=19.82 %

where

Invested Capital(A: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=121816.305 - 2315.243 - ( 49403.439 - max(0, 4229.146 - 70487.117+49403.439))
=70097.623

Invested Capital(A: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=132637.197 - 3220.495 - ( 51296.271 - max(0, 5281.955 - 71205.521+51296.271))
=78120.431

Square Pharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=20626.344 * ( 1 - 17.7% )/( (82565.293 + 85037.758)/ 2 )
=16975.481112/83801.5255
=20.26 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=140892.792 - 4321.96 - ( 54005.539 - max(0, 6760.413 - 77153.743+54005.539))
=82565.293

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=145571.284 - 13319.651 - ( 47213.875 - max(0, 15491.089 - 78983.484+47213.875))
=85037.758

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Square Pharmaceuticals  (DHA:SQURPHARMA) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Square Pharmaceuticals's WACC % is 10.54%. Square Pharmaceuticals's ROC % is 18.83% (calculated using TTM income statement data). Square Pharmaceuticals generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Square Pharmaceuticals ROC % Related Terms

Thank you for viewing the detailed overview of Square Pharmaceuticals's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Square Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Square Centre, 48, Mohakhali Commercial Area, Dhaka, BGD, 1212
Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceuticals products, Basic chemical products, and animal health products. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all living species. It manufactures drugs like paracetamol, clotrimazole, antiallergic, Nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs. Company also provides devices such as AnsuPen and AnsuPen Twist. The company operates in Bangladesh and sells its products locally and internationally.

Square Pharmaceuticals Headlines

No Headlines